New York-based pharma giant Pfizer (NYSE: PFE) will finally be able to complete its $43 billion acquisition of Seagen, having addressed all of the concerns of antitrust regulators.
The company said it expects the deal for the antibody-drug conjugate (ADC) developer to close tomorrow, after it agreed to donate the rights to Bavencio (avelumab) royalties to the American Association for Cancer Research (AACR).
Pfizer has already secured clearance from the European Commission, following a decision that was made in October.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze